Skip Navigation

Cardiovascular Research 2005 68(2):224-234; doi:10.1016/j.cardiores.2005.05.025
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ha, T.
Right arrow Articles by Li, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ha, T.
Right arrow Articles by Li, C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload

Tuanzhu Haa, Yuehua Lia, Fang Huaa, Jinag Maa, Xiang Gaob, Jim Kelleyc, Aiqiu Zhaod, Georges E. Haddadd, David L. Williamsa, I. William Browdera, Race L. Kaoa and Chuanfu Lia,b,*

aDepartment of Surgery, East Tennessee State University, Campus Box 70575, Johnson City, TN 37614-0575, USA
bAnimal Model Research Center, Nanjing University, 210093, China
cDepartment of Internal Medicine, East Tennessee State University, Johnson City, TN 37614, USA
dDepartment of Physiology and Biophysics, Howard University, Washington DC 20059, USA

* Corresponding author. Department of Surgery, East Tennessee State University, Campus Box 70575, Johnson City, TN 37614-0575, USA. Tel.: +1 423 439 6349; fax: +1 423 439 6259. Email address: Li{at}MAIL.ETSU.EDU

Objective: We have previously demonstrated that nuclear factor kappa B (NF{kappa}B) activation is needed for the development of cardiac hypertrophy in vivo. NF{kappa}B is a downstream transcription factor in the Toll-like receptor (TLR)-mediated signaling pathway; therefore, we investigated a role of TLR4 in cardiac hypertrophy in vivo.

Methods: TLR4-deficient mice (C.C3H-Tlr4lps-d, n = 6), wild-type (WT) genetic background mice (BALB/c, n = 6), TLR4-deleted strain (C57BL/10ScCr, n = 8), and WT controls (C57BL/10ScSn, n = 8) were subjected to aortic banding for 2 weeks. Age-matched surgically operated mice served as controls. In a separate experiment, rapamycin (2 mg/kg, daily) was administered to TLR4-deficient mice and WT mice immediately following aortic banding. The ratio of heart weight/body weight (HW/BW) was calculated, and cardiac myocyte size was examined by FITC-labeled wheat germ agglutinin staining of membranes. NF{kappa}B binding activity and the levels of phospho-p70S6K in the myocardium were also examined.

Results: Aortic banding significantly increased the ratio of HW/BW by 33.9% (0.601 ± 0.026 vs. 0.449 ± 0.004) and cell size by 68.4% in WT mice and by 10.00% (0.543 ± 0.011 vs. 0.495 ± 0.005) and by 11.8% in TLR4-deficient mice, respectively, compared with respective sham controls. NF{kappa}B binding activity and phospho-p70S6K levels were increased by 182.6% and 115.2% in aortic-banded WT mice and by 78.0% and 162.0% in aortic-banded TLR4-deficient mice compared with respective sham controls. In rapamycin-treated aortic-banded mice, the ratio of HW/BW was increased by 18.0% in WT mice and by 3.5% in TLR4-deficient mice compared with respective sham controls.

Conclusion: Our results demonstrate that TLR4 is a novel receptor contributing to the development of cardiac hypertrophy in vivo and that both the TLR4-mediated pathway and PI3K/Akt/mTOR signaling are involved in the development of cardiac hypertrophy in vivo.

KEYWORDS Toll-like receptor; Cardiac hypertrophy; Signaling pathways; Nuclear factor KappaB (NF{kappa}B); PI3K/Akt signaling pathway


Time for primary review 30 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
Y.-Y. Liu, W.-F. Cai, H.-Z. Yang, B. Cui, Z.-R. Chen, H.-Z. Liu, J. Yan, W. Jin, H.-M. Yan, B.-M. Xin, et al.
Bacillus Calmette-Guerin and TLR4 Agonist Prevent Cardiovascular Hypertrophy and Fibrosis by Regulating Immune Microenvironment
J. Immunol., June 1, 2008; 180(11): 7349 - 7357.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. Ha, F. Hua, X. Liu, J. Ma, J. R. McMullen, T. Shioi, S. Izumo, J. Kelley, X. Gao, W. Browder, et al.
Lipopolysaccharide-induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism
Cardiovasc Res, June 1, 2008; 78(3): 546 - 553.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Riad, S. Jager, M. Sobirey, F. Escher, A. Yaulema-Riss, D. Westermann, A. Karatas, M. M. Heimesaat, S. Bereswill, D. Dragun, et al.
Toll-Like Receptor-4 Modulates Survival by Induction of Left Ventricular Remodeling after Myocardial Infarction in Mice
J. Immunol., May 15, 2008; 180(10): 6954 - 6961.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. Takahashi
Toll-like receptors and myocardial contractile dysfunction
Cardiovasc Res, April 1, 2008; 78(1): 3 - 4.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
X. Yan, A. J. T. Schuldt, R. L. Price, I. Amende, F.-F. Liu, K. Okoshi, K. K. L. Ho, A. J. Pope, T. K. Borg, B. H. Lorell, et al.
Pressure overload-induced hypertrophy in transgenic mice selectively overexpressing AT2 receptors in ventricular myocytes
Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1274 - H1281.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
L. Timmers, J. P.G. Sluijter, J. K. van Keulen, I. E. Hoefer, M. G.J. Nederhoff, M.-J. Goumans, P. A. Doevendans, C. J.A. van Echteld, J. A. Joles, P. H. Quax, et al.
Toll-Like Receptor 4 Mediates Maladaptive Left Ventricular Remodeling and Impairs Cardiac Function After Myocardial Infarction
Circ. Res., February 1, 2008; 102(2): 257 - 264.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Padmasekar, R. Nandigama, M. Wartenberg, K.-D. Schluter, and H. Sauer
The acute phase protein {alpha}2-macroglobulin induces rat ventricular cardiomyocyte hypertrophy via ERK1,2 and PI3-kinase/Akt pathways*
Cardiovasc Res, July 1, 2007; 75(1): 118 - 128.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
F. Hua, T. Ha, J. Ma, Y. Li, J. Kelley, X. Gao, I. W. Browder, R. L. Kao, D. L. Williams, and C. Li
Protection against Myocardial Ischemia/Reperfusion Injury in TLR4-Deficient Mice Is Mediated through a Phosphoinositide 3-Kinase-Dependent Mechanism
J. Immunol., June 1, 2007; 178(11): 7317 - 7324.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Ha, F. Hua, D. Grant, Y. Xia, J. Ma, X. Gao, J. Kelley, D. L. Williams, J. Kalbfleisch, I. W. Browder, et al.
Glucan phosphate attenuates cardiac dysfunction and inhibits cardiac MIF expression and apoptosis in septic mice
Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1910 - H1918.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Ha, F. Hua, Y. Li, J. Ma, X. Gao, J. Kelley, A. Zhao, G. E. Haddad, D. L. Williams, I. W. Browder, et al.
Blockade of MyD88 attenuates cardiac hypertrophy and decreases cardiac myocyte apoptosis in pressure overload-induced cardiac hypertrophy in vivo
Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H985 - H994.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. J. van Oort and L. J. De Windt
TOLL-erating cardiac hypertrophy following pressure overload
Cardiovasc Res, November 1, 2005; 68(2): 178 - 179.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.